Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

Basit Öğe Kaydı
dc.contributor.authorGumus, M.
dc.contributor.authorKilickap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorHe, X.
dc.date.accessioned2024-05-19T14:39:53Z
dc.date.available2024-05-19T14:39:53Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpageS321en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue11en_US
dc.identifier.startpageS321en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4867
dc.identifier.volume18en_US
dc.identifier.wosWOS:001098831600537en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectCemiplimaben_US
dc.subjectAdvanceden_US
dc.subjectNsclcen_US
dc.subjectPatient-Reported Outcomesen_US
dc.titleDisease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu